Quarterly ResultAug 13, 2026, 04:18 PM
ProMIS Neurosciences Reports Positive PMN310 Interim Data; $53.4M Cash
AI Summary
ProMIS Neurosciences announced its second quarter 2026 financial results, reporting a net loss of $11.7 million and a net loss per share of $1.28. The company ended the quarter with a strong cash position of $53.4 million, which is expected to fund operations through 2027. Key corporate highlights included positive blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial for PMN310, showing no cases of ARIA-E and promising declines in Alzheimer's disease biomarkers.
Key Highlights
- Reported positive blinded six-month interim safety results for PMN310, with zero ARIA-E cases.
- Observed early, directionally consistent declines in plasma pTau217 (~15%) and CSF MTBR-tau243 (~13.3%).
- Ended Q2 2026 with $53.4 million in cash and short-term investments.
- Cash runway expected to fund operations through 2027, beyond Q1 2027 topline data.
- Net loss for Q2 2026 was $11.7 million, compared to $10.1 million in Q2 2025.
- Net loss per share was $1.28, down from $7.26 in Q2 2025 due to increased shares.
- Anticipates unblinded 12-month topline PRECISE-AD results in Q1 2027.
Price Impact
More from PMN